Abingdon, UK; 28 April 2020 - OBN, the Membership organisation supporting the UK’s innovative life sciences companies, is delighted to announce the launch of OBN Ventures Limited (OBNV).
OBNV is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform, provided by Envestors Ltd, which is designed to bring a wide range of investors together with early-stage life sciences and related companies that in some instances are yet to achieve any revenues and in the majority of cases will not have reached the point of profitability.
The OBNV platform is totally complementary in approach with OBN’s major investment conferences (BioTrinity® and BioSeed®) and offers the advantages of leveraging a wider range of investors and availability on a year-long basis.
OBNV should not be confused with a traditional crowd-funding website. All the investors participating in the OBNV platform are serious, professional investors (>6,000 and growing) who are credible, experienced, and actively looking for investable opportunities in the space.
The platform is open to all life sciences companies, but OBN Members will benefit from assistance in drafting and posting their offers and priority listing. OBNV’s core strategy is to focus on early stage life sciences companies with strong intellectual property (‘IP’), operating in attractive segments of £100m+ market potential or more, where the added value of OBNV / OBN may offer distinct advantage to investee companies.
John Harris, Investment Director of OBNV and CEO of OBN (UK) Ltd, commented:
“OBN is delighted to launch OBN Ventures™ with the mandate to deliver a state-of-the-art on-line investment platform generating much-needed funding for the life sciences sector. This significant initiative offers year-long access to a wide range of professional investors actively seeking investable opportunities. We believe this unique approach is a first for any life sciences membership organisation and further solidifies OBN’s leadership position in the sector.”
Oliver Woolley, CEO at Envestors, said:
“We are delighted to be working with OBNV. Our vision is to to create a ‘network of networks’ connecting entrepreneurs and investors across communities, sectors and geographies. The addition of the UK’s foremost life sciences organisation to our growing network is an important milestone and one that we know will be warmly welcomed by our existing partners and investors.”
To find out more about OBN Ventures then please take a look at the website or contact John Harris, Investment Director of OBN Ventures Ltd and CEO of OBN (UK) Ltd.
Rebecca Wilkes, Communications & Marketing Co-ordinator, OBN
Citigate Dewe Rogerson
About OBN Ventures:
OBN Ventures Ltd (OBNV) is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform which is designed to bring a wide range of professional investors together with early-stage life sciences and related companies that in some instances are yet to achieve any revenues and in the majority of cases will not have reached the point of profitability.
OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 400+ Member companies are located throughout the UK and benefit from our networking, partnering, purchasing, advising and advocacy activities.
OBN delivers four World-Quality flagships events per annum:
BioTrinity is Europe’s leading Biopartnering and Investment conference which will be held in London on 27-28 April 2021
BioForward is a high-quality international partnering conference providing a roadmap for R&D companies looking to achieve sustainable business growth (Oxford, 5 October 2020).
This is the UK’s leading Life Sciences awards event, celebrating innovation and outstanding achievement across the UK Life Sciences Industry (London, 26 November 2020).
BioSeed is a unique platform for early-stage life sciences companies, TTO’s, and Universities throughout Europe seeking equity investment from angels, HNW individuals, specialist crowd-funders, and PE / VC / Pharma funders genuinely interested in seed and series A funding (London, 26 January 2021).
Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk